The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...
LillyDirect’s Jennifer Mazur on the platform’s new partnership with Walmart, future of DTC platforms
Mazur, GM of LillyDirect, breaks down the platform’s new partnership with Walmart and its implications for the pharma ...
In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...
Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...
The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...
Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Eduardo ...
United States President Donald Trump’s planned tariffs on pharmaceuticals have disrupted the industry. Here’s a timeline of ...
Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals ...
By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...
The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback